In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.

Biomed Chromatogr 2007 Feb;21(2):190-200

Laboratory of Pharmacology, School of Medicine, Faculty of Health Sciences, University of Thessaly, 22 Papakiriazi St, 41222 Larissa, Greece.

A RP-HPLC method was developed for the assessment of caffeine and its metabolites in urine and was used for the evaluation of the CYP1A2, CYP2A6, xanthine oxidase (XO) and N-acetyl-transferase-2 (NAT-2) in vivo activities in 44 Greek volunteers (21 men, 23 women). Spot urine samples were analyzed 6 h after 200 mg caffeine consumption, following a 30 h methylxantine-free diet. The major urinary caffeine metabolites are 1-methyluric acid (1U), 5-acetylamino-6-formylamino-3-methyluracil (AFMU), 1-methylxanthine (1X), 1,7-dimethyluric acid (17U) and 1,7-dimethylxanthine (17X). CYP1A2, CYP2A6, XO and NAT-2 activities were estimated from the metabolic ratios (AFMU + 1U + 1X)/17U, 17U/17X, 1U/(1X + 1U) and AFMU/(AFMU + 1U + 1X), respectively. Metabolites and internal standard were extracted with chloroform/isopropanol (85:15, v/v) and separated on a C18 column by an isocratic HPLC system using a two-step elution with manual switch from solvent A (0.1% acetic acid-methanol-acetonitrile, 92:4:5 v/v) to solvent B (0.1% acetic acid-methanol, 60:40, v/v), and detected at 280 nm. The method exhibited adequate metabolite separation (resolution factors >1.48), accuracy (94.1-106.3%) and intraday and interday precision <8.02 and <8.78%, respectively (n = 6). Smoking affected only CYP1A2, whereas gender had no effect in any enzyme activity. NAT-2 exhibited bimodal distribution, 63.6% of volunteers being slow acetylators. The developed RP-HPLC method was fully validated and successfully applied for the evaluation of CYP1A2, CYP2A6, XO and NAT-2 activities.

Download full-text PDF

Source
http://dx.doi.org/10.1002/bmc.736DOI Listing
February 2007
2 Reads

Publication Analysis

Top Keywords

cyp1a2 cyp2a6
12
solvent 01%
8
xanthine oxidase
8
01% acetic
8
metabolic ratios
8
activities greek
8
cyp2a6 nat-2
8
evaluation cyp1a2
8
caffeine metabolites
8
17-dimethyluric acid
4
17x cyp1a2
4
17-dimethylxanthine 17x
4
acid 17u
4
17u 17-dimethylxanthine
4
280 method
4
detected 280
4
ratios afmu
4
afmu 1x/17u
4
estimated metabolic
4
activities estimated
4

References

(Supplied by CrossRef)

Aklillu et al.
European Journal of Clinical Pharmacology 2003

Ambrose et al.
Journal of Chromatography B Biomedical Sciences and Applications 1998

Aoyama et al.
Proceedings of the National Academy of Sciences, USA 1990

Asprodini et al.
European Journal of Drug Metabolism and Pharmacokinetics 1998

Baud-Camus et al.
Journal of Chromatography B Biomedical Sciences and Applications 2001

Bechtel et al.
International Journal of Clinical Pharmacology and Therapeutics 2000

Bendriss et al.
Journal of Chromatography B Biomedical Sciences and Applications 2000

Bertilsson et al.
British Journal of Clinical Pharmacology 1994

Bonati et al.
Clinical Pharmacological and Therapeutics 1982

Butler et al.
Proceedings of the National Academy of Sciences, USA 1989

Campbell et al.
Drug Metabolism and Disposition 1987a

Similar Publications